{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:32:41Z","timestamp":1783474361374,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,7,8]],"date-time":"2018-07-08T00:00:00Z","timestamp":1531008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the activity of high\u2010density lipoprotein (HDL)\u2013associated paraoxonase 1 (PON1) in patients with psoriasis (PsO) and patients with psoriatic arthritis (PsA), and to evaluate the association of PON1 activity with the extent of disease activity and severity of the cardiovascular disease (CVD) burden in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum levels of paraoxonase and arylesterase activity (both measures of PON1 function in humans) were measured in patients with PsA (n = 198, 51.0% male) and patients with PsO (n = 145, 50.3% male) who were enrolled in a longitudinal psoriatic disease biorepository. Data on PsA disease activity (using the Disease Activity Score in 28 joints [DAS28], Clinical Disease Activity Index, and painful\/swollen joint counts), preexistent CVD and CVD risk factors (including diabetes, dyslipidemia, hypertension, and smoking), Framingham Risk Scores for CVD, quality of life measures, and laboratory test findings (erythrocyte sedimentation rate, C\u2010reactive protein level, and lipid profiles) were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum arylesterase activities were significantly lower in patients with PsO and patients with PsA (mean \u00b1 SD 111.1 \u00b1 25.5 \u03bcmoles\/minute\/ml and 124.4 \u00b1 33.4 \u03bcmoles\/minute\/ml, respectively) compared to healthy controls (144.3 \u00b1 33.4 \u03bcmoles\/minute\/ml) (each <jats:italic>P<\/jats:italic> &lt; 0.001 versus healthy controls). Serum arylesterase activity decreased in parallel with increasing levels of disease activity (DAS28 scores, <jats:italic>P<\/jats:italic> = 0.012), older age (<jats:italic>P<\/jats:italic> = 0.013), higher body mass index (<jats:italic>P<\/jats:italic> = 0.042), greater incidence of metabolic syndrome (<jats:italic>P<\/jats:italic> = 0.004) and hypertension (<jats:italic>P<\/jats:italic> = 0.014), and worsening Framingham Risk Scores (<jats:italic>P<\/jats:italic> = 0.001). However, no correlation was seen between serum arylesterase activity and the extent of disease activity or CVD burden in patients with PsO. Serum paraoxonase activity trended lower both in patients with PsO and in patients with PsA (each <jats:italic>P<\/jats:italic> = 0.073 versus healthy controls). However, no association was seen between serum paraoxonase activity and the extent of disease activity or CVD burden in either of the patient cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PON1 activity is decreased in psoriatic diseases. In the PsA cohort, decreases in arylesterase activity correlated with increasing severity of joint disease and CVD burden. Arylesterase activity, as compared to paraoxonase activity, appeared to serve as a more sensitive predictor of preexisting CV risk factors in the PsA cohort. However, this correlation was not observed in the PsO population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40499","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T06:36:52Z","timestamp":1521787012000},"page":"1240-1250","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Correlation of High\u2010Density Lipoprotein\u2013Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease"],"prefix":"10.1002","volume":"70","author":[{"given":"M. Elaine","family":"Husni","sequence":"first","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Wilson Tang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lucke","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. M.","family":"Chandrasekharan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brennan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Hazen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.053"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.149"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.020"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000163262.83456.6d"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.4.473"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421109"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.17.2136"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32832ca1ee"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.253930"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-379"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00195-4"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39609"},{"key":"e_1_2_6_14_1","first-page":"BC01","article-title":"Correlation of paraoxonase status with disease activity score and systemic inflammation in rheumatoid arthritic patients","volume":"10","author":"Bindal UD","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2005.06.010"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.016"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21889"},{"key":"e_1_2_6_18_1","first-page":"719","article-title":"Anti\u2010apolipoprotein A\u2010I antibodies and paraoxonase 1 activity in systemic lupus erythematosus","volume":"12","author":"Ahmed MM","year":"2013","journal-title":"EXCLI J"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0229-0"},{"key":"e_1_2_6_20_1","first-page":"145","article-title":"Study of lipid profile and paraoxonase\u20101 activity in psoriatic patients","volume":"6","author":"Arora M","year":"2015","journal-title":"IJBAR"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.09.008"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.1553"},{"key":"e_1_2_6_23_1","first-page":"4001","article-title":"Evaluation of serum paraoxonase level and dyslipidemia in psoriasis","volume":"4","author":"Prathibha K","year":"2016","journal-title":"Int J Res Med Sci"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322010000200009"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v34i4.15364"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2591-1"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141532"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006296"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(89)90424-7"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000097034"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094585"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409065"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2001"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.537878"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.11.1265"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.958348"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38118"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.777"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21976"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24677"},{"key":"e_1_2_6_50_1","first-page":"34","article-title":"HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis","volume":"6","author":"Mani P","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202325"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22144"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:29:00Z","timestamp":1759926540000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/art.40499"],"URL":"https:\/\/doi.org\/10.1002\/art.40499","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,8]]},"assertion":[{"value":"2017-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}